Introduction:
Celiac disease (CD) is a systemic immune-mediated disorder which is triggered by gluten and other prolamines in wheat, barley, rye, and other cereals in genetically susceptible individuals. CD has systemic effects but is mainly characterized by enteropathy with villous atrophy that may result in malnutrition, diarrhea, weight loss, growth retardation, and other symptoms such as constipation or fatigue [1] . The only known effective treatment is a lifelong, strict gluten-free diet (GFD) [2] . Environmental and genetic factors play an important role in the pathogenesis of CD. Apart from the main environmental trigger gluten, a protein complex formed by gliadins and glutenins [3] , other environmental factors such as breastfeeding, time of gluten introduction, or the mode of delivery have been proposed to be associated with the risk for CD. While the influence of some of these environmental factors is being clarified or is still a question of debate [4, 5] , the relevance of the risk alleles of the Human Leukocyte Antigen (HLA)-DQ2 and HLA-DQ8 for the development of CD is well established: Over 90% of CD patients carry the alleles encoding HLA-DQ2 molecule; most of the remaining CD patients carry the HLA-DQ8 heterodimers. However, although around 25% of the European general population is positive for the HLA-DQ2 heterodimer (and ~50% if HLA-DQ8 is also included), only a small fraction (~1%) will develop CD [6] [7] [8] . This indicates that the HLA-DQ2 and/or HLA-DQ8 risk alleles are necessary but not sufficient for the development of the disease [3] . Thus, other genetic and/or environmental factors besides gluten must be involved in the pathogenesis of CD and a closer investigation of the mechanisms involved in the activation and development of the disorder is needed.
Metabolomics, the study of small-molecule metabolite profiles, facilitates the characterization of several pathological conditions such as obesity or cardiovascular diseases [9, 10] . The metabolites are intermediates and end products of cellular regulatory processes, and their levels can be regarded to be the result of the interaction of genome, transcriptome, proteome, and the environment [11, 12] . Investigating the metabolic profile of CD patients is thus a logical consequence. So far, only few studies investigated the differences in metabolic profiles between CD patients and healthy controls [13] , and even fewer studies focused on the serum metabolic profile. The results of those studies, however, 6 are quite promising revealing alterations in energy metabolism [14] and suggesting that metabolic alterations may precede the development of small intestinal villous atrophy [15] .
Besides this cross-sectional view, it is also of major interest to investigate whether the metabolic profiles of children, who will progress to CD later in life, differ already at early age.
The identification of metabolic markers would represent a significant advance and targets for early interventions and preventive strategies. For instance, studies on type 1 diabetes which shares common alleles with CD have identified metabolic phenotypes that characterize the early pathogenesis of the disease [16, 17] . Using data from the prospective cohort of the PreventCD study, we tested if the metabolic profile of 4 month old children at genetic risk for CD was associated with (1) the development of CD up to school age, (2) the HLA-risk groups, or (3) the age at CD diagnosis.
Material and Methods

Study design
The PreventCD project is a prospective, randomized, double-blind, placebo-controlled, dietary-intervention study in children with high risk for CD [5, 18] . The first child was included on May 26, 2007 , and the follow-up for this analysis closed on August 26th, 2015.
Recruitment of the infants was done consecutively through CD organizations in Croatia, Germany, Hungary, Israel, Italy, the Netherlands, Poland, and Spain. Newborns between 0-3 months of age were recruited if (i) they had at least one first-degree family member with CD confirmed by small-bowel biopsy, and (ii) were HLA-DQ2 or HLADQ8 positive, or otherwise carrying the allele DQB1*02 [18] . Premature infants or infants with syndromes associated with an increased risk of CD, such as trisomy 21 or Turner's syndrome, were excluded. The infants were randomized to the intervention groups and either received gluten (200 mg of vital wheat gluten mixed with 1.8 g of lactose) or placebo (2g of lactose) between 4 and 6 months of age. Randomization took place after blood withdrawal.
The study was approved by the medical ethics committee at each participating center and complied with Good Clinical Practice guidelines. The authors vouch for the veracity and completeness of the data and analyses reported and for the adherence of the study to the protocol.
Assessment of CD
Children with elevated levels of antibodies indicating CD and/or with clinical suspicion of CD are offered to undergo a small-bowel biopsy to diagnose the disorder. The diagnosis of CD was based on the histologic findings of the small-bowel biopsies, according to the criteria of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) [19] . The age of the patient at the day of biopsy is considered to be the age at the diagnosis of CD.
Genotyping
Genotyping for HLA-DQ-alleles was performed by single nucleotide polymorphisms (SNPs) based on the tag-SNP approach (Department of Genetics University Medical Center Groningen, the Netherlands). The HLA-risk groups were defined as follows: (1) We took advantage of this collection for the purpose of this study. The sera of these 4 month old infants collected before the start of the dietary intervention were transferred on dry ice to LMU Munich and stored at -80°C until metabolomic analysis.
Analysis of AA was performed as described previously [21] . Briefly, 10µl of serum was prepared by derivatization to amino acid butylester, and determined by ion-pair liquid chromatography (LC). The LC system (Agilent, Waldbronn, Germany) was coupled to a tandem mass spectrometer (MS/MS, QTRAP4000, Sciex, Darmstadt, Germany) with an During the quantification processes, the samples of the study centers were randomly distributed across the batches. The entire analytical process was post-processed by the softwares Analyst 1.5.1 and R 3.2.1. To remove the batch effect, we centered the metabolomics data for analysis by subtracting for each metabolite its mean concentration across all batches. Analytes, for which we had measurements for less than 10% of the infants only, were excluded from the analyses. All metabolite concentrations are reported in µmol/L.
Statistical analyses
In a first step, the data was examined graphically and screened for outliers. We defined a measurement as outlier if its absolute concentration exceeds one standard deviation (SD) away from its neighbor. Baseline characteristics of the children are presented as mean (SD) or count (percentage), for continuous and categorical variables, respectively.
In a first analysis, we investigated if the metabolic profile was associated with the development of CD up to the age of 8 years, coded binary (yes/no). In a second analysis, we examined if the metabolic profile depended on the HLA-risk group. In both analyses, we used linear mixed models (LMM) with random intercept for study center and regressed the metabolite's concentration on the (1) binary CD y/n variable and the (2) categorical HLA-risk group variable. When analyzing the sum parameters, we used the non-batch centered data and calculated LMM with two independent random intercepts for study center and batch number. As the HLA-risk groups sizes were very unequal, we chose the biggest, namely risk group 3, as reference category. ANOVA was used to test for differences between the HLArisk groups. Possible confounding factors that were considered in both analyses comprised gender, maternal CD status, and age at blood withdrawal. We furthermore applied cox proportional hazards models where we investigated if the metabolite concentration was associated with the time to the CD diagnosis (i.e. the age at diagnosis). In these models, we additionally considered intervention group as confounding factor. Bonferroni correction was applied to all analyses in order to control for false positives. Thus, a P-value of below 0.05/183 = 0.00027 was considered to be statistically significant. Furthermore, as the aforementioned LMM only consider one metabolite at a time, we performed sensitivity analyses using partial least squares discriminant analysis and random forest. Random forest was calculated the same way as described in Kirchberg et al. [22] .
The three analyses were each performed on the whole sample and on a subgroup, defined as follows: Firstly, the infant had to be exclusively breastfed up to the age of 4 month; Secondly, the mother had to be either on a GFD and being CD positive, or not being on a GFD and being healthy (n=174).
We presented our results graphically in a circular Manhattan Plot summarizing the results of the three approaches. Every metabolite is given a position on the outer circle and three points, each indicating a -log 10 (P) value from a model, are positioned on the line connecting the metabolite to the center. Significance can be read by looking at the significance lines at α=0.05 and α=0.00027 (Bonferroni corrected). If a point lies further out than the line, it is significant to the corresponding significance level α.
Results
Blood samples were available for 230 children. Baseline characteristics of those infants are listed in Table 1 . The mean age at blood withdrawal was 122.3 days (SD, 25.72 d). Up to that day, 184 children (80%) were exclusively breastfed. Among those, 90 mothers were diagnosed with CD and were on a GFD diet, and 84 mothers were healthy and hence not on a GFD diet. The remaining 10 mothers were either on a GFD although being healthy (n=1),
were not on a GFD although having been diagnosed with CD (n=4), or information on their diet was missing (n=5). By the end of 2014, and when the children were aged on average 6.5 years (SD, 0.69 yrs), thirty-three out of these 230 children (14%) were diagnosed with CD according to the ESPGHAN criteria. The mean age at diagnosis was 3.8 years (median, 3.4 yrs; IQR, 2.3-5.2 yrs) and youngest age at diagnosis was 1.8 years of age. Of the 174 children who were exclusively breastfed and whose mother subsisted according to her CD status, 23 (13%) were diagnosed with CD. Children comprised in the subsample were not different to those not comprised with respect to the baseline characteristics listed in Table 1 (data not shown). Regarding the HLA-risk groups, 13% were in the highest risk group. Most children were in the risk group 3 (52%).
Metabolic profile in relation to a later CD diagnosis and the HLA-risk group
The metabolic profiles between children with and without a later CD diagnosis or between the five HLA-risk groups were not different (all corrected P = 1; Supplemental Table 1 & 2) . This result did not change in the multivariate LMM where we additionally adjusted for gender, maternal CD status, and age at blood withdrawal. The P -values for both analyses are represented graphically in the circular Manhattan-Plot (Figure 1 ): Although some metabolites differed at the uncorrected significance level of α=0.05, these differences were far away from significance after correcting for multiple testing. Table 2 and 3 summarize the concentrations of these metabolites. Regarding the differences between infants with and without development of CD up to school age (Table 2 ) all of these metabolites are phosphatidylcholines. Among children who were exclusively breastfed up to 4 month of age and whose mothers had a diet consistent to the CD status (thus, were on a GFD and had a CD diagnosis, or were not on a GFD but had a CD diagnosis), this observation becomes even clearer: Some metabolites almost reached the Bonferroni-corrected significance level (Supplemental Figure 1) . For instance, the corrected P-value comparing the concentration of the acyl-alkyl phosphatidylcholine PCae C42:6 between children who will and those who won't develop CD in comparison to healthy infants was 0.08. The calculation of the absolute sum of the phosphatidylcholine species (Figure 2 ) revealed that the mean sums were lower in those infants who will develop CD later in life. This difference, however, was not significant at the corrected significance level, neither in the whole nor in the subsample (Supplemental Figure 2) . The (percent) phospholipid composition also was not different (Supplemental Table 3 ).
The ensemble approach, the random forest analysis, also confirmed the non-discriminating nature of the metabolome and dispels the impression from the subsample analysis, this is, different phospholipid levels in healthy and CD children: The out-of-bag error rate of 13% (11% in the subsample) equaled in both cases the percentage of CD diagnosis among the studied infants. Thus, random forest was not able to classify correctly CD and healthy children but classified everyone as healthy. Table 3 summarizes the results of selected LMM on the HLA-risk groups. The concentrations are similar across the groups (all corrected P-values > above 0.05).
Relating the metabolic profile at 4 month of age with the age at diagnosis
Using cox proportional hazards models, we modelled the predictive power of the metabolite's concentrations on the time to onset of CD. No significant effect was found after Bonferroni correction (Figure 1 ). In fact, significances were similar to those of the LMM which ignores missing data originating from the censoring. Table 2 summarizes the hazard ratios and significances of selected metabolites and underlines this similarity.
Discussion
In this investigation on the metabolic preconditions of CD, neither a single metabolite nor any tested combination of metabolites was associated with the CD status at school age, or with the age at CD diagnosis. The HLA-risk group also had no effect on the metabolites' serum concentration.
To our knowledge, there have been no previous studies that examined the associations of early metabolic markers in the blood with a later CD diagnosis. Some publications focus on the metabolic fingerprint for CD in one of the matrices serum, urine, or gut microbiota, but they compare CD patients (potential or overt) with healthy controls [14, 15] . Their design differs from ours in that it is cross sectional rather than prospective. Calabro et al [13] provide a summary of these studies and conclude that there is clear evidence for an altered metabolism with respect to malabsorption, energy metabolism, and alterations in gut microflora and/or intestinal permeability. Two studies investigated the serum metabolic profile: Bertini [14] found differences in the plasma metabolic profiles of CD patients and healthy controls; particularly glycolysis was reduced in untreated CD patients. The consequently increased beta-oxidation along with malabsorption was suggested to be the reason for decreased lipids in sera and an increase in the ketone body 3-hydroxybutyric acid.
Introducing a GFD led to a normalization of the main energy metabolic pathway and a recovery of villous functioning. Bernini et al [15] put emphasis on the precondition of CD and compared healthy subjects with those having potential or overt CD. Potential CD patients, having the typical immunological features of clear CD in the absence of any apparent intestinal damage, were found to have a virtually similar metabolic profile as the patients with overt CD. They suggest that metabolic and enterocyte alterations of CD arise before the observable modification of jejunal mucosa.
In contrast to these studies, we focused on the alteration of pathways prior to the presence of specific CD antibodies (IgA tissue transglutaminase) or CD onset and, according to the best of our knowledge, we are the first to examine potential metabolic preconditions for CD development in very young infants at genetic risk. Although the results of the cited previous studies point towards alterations in the metabolic profile of CD patients, our findings do not show any such changes in infants aged 4 months prior to dietary gluten introduction. We observed a trend to decreased phospholipid levels in children who later developed CD.
However, we strongly emphasize that all corrected P-values were above 0.05, no matter which analysis we performed, including those for the sums of the phospholipid species. As the results were stronger in the subsample of mainly exclusively breastfed children, it seems that the consumption of liquids or foods other than breastmilk reduces this trend. To exclude a potential influence of a different maternal diet and breastmilk composition of CD mothers, we adjusted the analyses for the maternal CD status and gluten-free diet, but this was also not associated to any metabolite concentration. Decreased phospholipid levels, including phosphatidylcholines and sphingomyelins which both contain fatty acid (FA) chains, have been found in cord blood of children who later progress to type 1 diabetes, a disease which is also associated with the HLA class II genes [17, 23] . There are no comparable studies on CD. Studies on the FA composition in CD patients have found ambiguous results: While some found evidence for an altered serum FA composition in adults with CD [24] [25] [26] , Steel et al [27] found a similar serum profile of FA in phospholipids in CD and control children. We could not identify any distinct FA species among the phosphatidylcholines ( Table 2) . Phospholipid composition was also not associated to the CD status at school age. Tjellström et al [28] who focus on children who already developed CD found a different fecal pattern of some short chain fatty acids (SCFA) between untreated CD children and healthy controls which may reflect bacterial metabolism of undigested carbohydrates secondary to CD-induced malabsorption. This however is not expected to exists at the age of 4 month prior to gluten introduction. SCFA are products of microbial degradation of complex carbohydrates in the colon and, while butyrate mainly feeds the enterocytes, acetate and propionate are transported to peripheral organs for gluconeogenesis, lipogenesis and other metabolic and immune response pathways [29, 30] .
It is very likely that this effect would have led to respective alterations in the patterns of esterified serum lipids and acylcarnitines which we did not observe. Therefore, we assume that no major alterations in SCFA are present in 4 month old infants with high risk for CD before gluten introduction. However, further studies measuring serum SCFA are needed to gain certainty on this point.
Regarding the genotype, there were no metabolomic differences across the HLA-risk groups, thus the HLA-DQ genotype does not directly cause the altered metabolism observed later in CD patients. The main genetic predisposing factors are the HLA-DQ alleles accounting for 18% of the genetic risk [31] . Individuals with HLA-DQ2/DQ-8 haplotypes have increased immunological responsiveness to prolamins such as dietary wheat gliadin due to the CDassociated HLA-DQ molecules that bind gluten peptides with a superior ability than the other HLA-molecules [3] . It was found that the HLA-DQ genotype influences the early gut microbial colonization [32, 33] . As the metabolome is influenced by the microbiome [34] , these findings suggest an altered metabolic profile according to the HLA-risk group which however was not confirmed by this study of infants early before onset of CD. Besides the HLA-genes, also other loci are associated to CD. The total genetic variation is estimated to explain up to 48% of CD heritability [31] . Regulatory mechanisms of CD development may also be modulated by epigenetics and microbiota [6, 35] .
The strength of this study lies in its prospective character, the long follow-up of up to 8 years, and in the broad assessment of CD related factors, such as information on the mother's diet and CD status as well as the child's HLA-genotype. CD cases were all assessed in an identical way which minimizes the risk of bias. The majority of the infants were exclusively breastfed up to blood withdrawal. Having a sufficient sample size to analyze the children with exclusive breastfeeding and hence to reduce diet induced metabolic variation, we were able to investigate the association of the metabolome not yet influenced by liquids or foods other than breastmilk and future CD development.
Conclusions
Our findings do not support a relation of the metabolic profile at age of 4 month prior to gluten-consumption, neither with respect to a future CD development nor with respect to the genotype. Performing metabolomics profiling longitudinally at several time points might help to better capture the dynamics of the CD development. With respect to the attempts to understand and prevent the development of CD, our results lead us to the conclusion that metabolic investigations should focus on children after the introduction of gluten. 2) LMM testing for the differences in the respective serum metabolite across the HLA-risk groups as defined in Bourgey (2007) ("HLA"); (3) Cox proportional hazards models assessing the effect of the respective metabolite on age at CD diagnosis ("Cox"). LMM were adjusted for gender, maternal CD status, and age at blood withdrawal. Cox proportional hazards models were adjusted for gender and intervention group. Significance is indicated by the grey dashed line (α=0.05), and the black dashed line (Bonferroni-corrected α=0.000027).The center represents an uncorrected P-value of 1.
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Abbreviations: Carn, acylcarnitine; LPC, lysophosphatidylcholine; PCaa, diacyl-phosphatidylcholine; PCae, acylalkyl-phosphatidylcholine; SM, sphingomyeline Figure 2 : Scatterplot of the sum of diacyl-phosphatidylcholines (PCaa), acyl-alkylphosphatidylcholines (PCae), and all phosphatidylcholines (PC) versus the age at diagnosis (if child was diagnosed celiac disease [CD]; cross) or age at analysis (if child was not diagnosed CD up to that date; triangle). Boxplots show the distribution among the groups. Significance for group difference was assessed with linear mixed models adjusted for gender, maternal CD status, and age at blood withdrawal.
